The National Cancer Institute (NCI) is offering this grant for exploratory, early-stage research developing highly innovative technologies. This grant is for improving biospecimen sample quality in basic and clinical cancer research. It addresses pre-analytical degradation during collection, processing, and storage to maximize sample utility. The goal is to develop tools, devices, and methods to preserve integrity or establish robust quality assessment. These technologies will accelerate cancer research across various domains, from biology to treatment and health disparities, by reducing pre-analytical variations. This initiative is part of NCI’s Innovative Molecular Analysis Technologies (IMAT) Program.
Opportunity ID: 344757
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-23-004 |
| Funding Opportunity Title: | Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 02, 2022 |
| Last Updated Date: | Dec 02, 2022 |
| Original Closing Date for Applications: | Sep 01, 2023 |
| Current Closing Date for Applications: | Sep 01, 2023 |
| Archive Date: | Oct 07, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Private institutions of higher education State governments Small businesses Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments County governments Special district governments Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-004.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278762 | Feb 01, 2023 | Sep 01, 2023 | View |
Package 1
Mandatory forms
344757 RR_SF424_5_0-5.0.pdf
344757 PHS398_CoverPageSupplement_5_0-5.0.pdf
344757 RR_OtherProjectInfo_1_4-1.4.pdf
344757 PerformanceSite_4_0-4.0.pdf
344757 RR_KeyPersonExpanded_4_0-4.0.pdf
344757 RR_Budget_3_0-3.0.pdf
344757 PHS398_ResearchPlan_5_0-5.0.pdf
344757 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
344757 RR_SubawardBudget30_3_0-3.0.pdf
344757 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
